•
IMPDH Enzymes
Inosine Monophosphate Dehydrogenase (IMPDH) (E.C.1.1.1.205) catalyzes the conversion of inosine 5’-monophosphate (IMP) to xanthosine 5’- monophosphate (XMP), which is a crucial step for guanosine biosynthesis and for the pool of guanine nucleotides.
In Human, IMPDH is a validated target for several therapeutic applications (cancer, immunological disorders...). Several IMPDH inhibitors, including blockbusters (e.g. CellCept®), have shown their clinical efficacy. Besides nucleoside (or NAD) analogues, new chemical entities (NCEs) have been identified as efficient IMPDH inhibitors and are currently investigated.
Mammalian and bacterial IMPDHs are known to have significantly different kinetic properties and inhibitor sensitivities(1, 2). NOVOCIB provides two recombinant IMPDH enzymes: Human IMPDH, Type II, and Staphylococcus aureus IMPDH. These two enzymes are useful tools for selection of species-specific IMPDH inhibitors.
Inosine Monophosphate Dehydrogenase (IMPDH) (E.C.1.1.1.205) catalyzes the conversion of inosine 5’-monophosphate (IMP) to xanthosine 5’- monophosphate (XMP), which is a crucial step for guanosine biosynthesis and for the pool of guanine nucleotides.
Mammalian and bacterial IMPDHs are known to have significantly different kinetic properties and inhibitor sensitivities(1, 2). NOVOCIB provides two recombinant IMPDH enzymes: Human IMPDH, Type II, and Staphylococcus aureus IMPDH. These two enzymes are useful tools for selection of species-specific IMPDH inhibitors.
Click here below to know more about...
...or download our brochure "NovoCIB's IMPDH Products & Services" 
